{"id":"tp-55860","type":"article-newspaper","title":"EyePoint Expects COMO, CAPRI Phase 3 Data in Early Q4 2027","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/55860","datePublished":"2026-11-12T20:21:05.000Z","dateModified":"2026-11-12T20:21:05.000Z","language":"en","abstract":"The company is focusing its Phase 3 program on DURAVYU for diabetic macular edema.","section":"Business","references":[]}